This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Noel, G. J.
Right arrow Articles by Solomkin, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Noel, G. J.
Right arrow Articles by Solomkin, J. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2008, p. 37-44, Vol. 52, No. 1
0066-4804/08/$08.00+0     doi:10.1128/AAC.00551-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria{triangledown}

Gary J. Noel,1* Richard S. Strauss,1 Karen Amsler,1 Markus Heep,2 Rienk Pypstra,2 and Joseph S. Solomkin3

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey,1 Basilea Pharmaceutica Ltd., Basel, Switzerland,2 University of Cincinnati College of Medicine, Cincinnati, Ohio3

Received 25 April 2007/ Returned for modification 27 July 2007/ Accepted 12 September 2007

Ceftobiprole is the first broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA) to be assessed in late-stage clinical trials. As a pivotal step in the clinical development of ceftobiprole, a multicenter, global, randomized, double-blind trial was conducted to compare the efficacy of ceftobiprole to that of vancomycin in patients with complicated skin and skin structure infections (cSSSIs) caused by gram-positive bacteria. The primary objective was to assess noninferiority on the basis of the cure rates 7 to 14 days after the completion of therapy in patients administered ceftobiprole 500 mg every 12 h or vancomycin 1 g every 12 h. Of 784 patients randomized, 282 receiving ceftobiprole and 277 receiving vancomycin were clinically evaluable. Of these patients, 93.3% treated with ceftobiprole and 93.5% treated with vancomycin were cured (95% confidence interval of difference, –4.4%, 3.9%). The cure rates for patients with MRSA infections were 91.8% (56/61) with ceftobiprole treatment and 90.0% (54/60) with vancomycin treatment (95% confidence interval of difference, –8.4%, 12.1%). At least one adverse event (AE) was reported by 52% of the ceftobiprole-treated patients and 51% of the vancomycin-treated patients. The most common AEs reported by the ceftobiprole-treated patients were nausea (14%) and taste disturbance (8%). Discontinuation of the study drug because of treatment-emergent AEs occurred in 4% (n = 17) of the ceftobiprole-treated patients and 6% (n = 22) of the vancomycin-treated patients. The results of this trial support the use of ceftobiprole as an effective and well-tolerated treatment option for patients with cSSSIs caused by a spectrum of gram-positive bacteria.

* Corresponding author. Mailing address: Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 900 Route 202, Raritan, NJ 08869. Phone: (908) 704-4316. Fax: (908) 595-0843. E-mail: GNoel1{at}prdus.jnj.com

{triangledown} Published ahead of print on 22 October 2007.

Antimicrobial Agents and Chemotherapy, January 2008, p. 37-44, Vol. 52, No. 1
0066-4804/08/$08.00+0     doi:10.1128/AAC.00551-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Zhanel, G. G., Voth, D., Nichol, K., Karlowsky, J. A., Noreddin, A. M., Hoban, D. J. (2009). Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother 64: 364-369 [Abstract] [Full Text]  
  • Barbour, A., Schmidt, S., Sabarinath, S. N., Grant, M., Seubert, C., Skee, D., Murthy, B., Derendorf, H. (2009). Soft-Tissue Penetration of Ceftobiprole in Healthy Volunteers Determined by In Vivo Microdialysis. Antimicrob. Agents Chemother. 53: 2773-2776 [Abstract] [Full Text]  
  • Kimko, H., Murthy, B., Xu, X., Nandy, P., Strauss, R., Noel, G. J. (2009). Population Pharmacokinetic Analysis of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 53: 1228-1230 [Abstract] [Full Text]  
  • Amsler, K. M., Davies, T. A., Shang, W., Jacobs, M. R., Bush, K. (2008). In Vitro Activity of Ceftobiprole against Pathogens from Two Phase 3 Clinical Trials of Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 52: 3418-3423 [Abstract] [Full Text]  
  • Leonard, S. N., Cheung, C. M., Rybak, M. J. (2008). Activities of Ceftobiprole, Linezolid, Vancomycin, and Daptomycin against Community-Associated and Hospital-Associated Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 2974-2976 [Abstract] [Full Text]  
  • Anderson, S. D, Gums, J. G (2008). Ceftobiprole: An Extended-Spectrum Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin. The Annals of Pharmacotherapy 42: 806-816 [Abstract] [Full Text]  
  • (2008). Ceftobiprole vs. Vancomycin for Complicated Skin Infections. JWatch Infect. Diseases 2008: 1-1 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»